分享好友 环球市场首页 环球市场分类 切换频道

Global Kidney Stone Retrieval Devices Market

2025-06-2400

Global Kidney Stone Retrieval Devices Market Analysis

The kidney stone retrieval devices market stood at USD 3.07 billion in 2025 and is projected to reach USD 3.87 billion by 2030, advancing at a 4.7% CAGR during the forecast period. Sustained momentum in the kidney stone retrieval devices market arises from the climbing incidence of urolithiasis in ageing populations, the ongoing shift toward minimally-invasive treatment pathways, and the swift roll-out of single-use flexible ureteroscopes, thulium-fiber lasers, and other purpose-built retrieval accessories. Broader reimbursement—illustrated by CMS transitional pass-through payments for single-use scopes—reduces economic barriers, while outpatient centers capture a rising proportion of routine stone procedure. Competitive intensity in the kidney stone retrieval devices market stays moderate as Boston Scientific, Olympus Corporation, Cook Medical, and other leaders combine hardware innovation, physician training, and geographic expansion to widen procedural reach. Cost headwinds linked to premium digital scopes and volatile nitinol supply chains persist, yet cost-effective single-use options and steadily improving reimbursement dilute downside risk.

Key Report Takeaways

  • By device type, ureteroscopes led with 34.45% of the kidney stone retrieval devices market share in 2024, while lithotripters are forecast to expand at a 5.34% CAGR through 2030.
  • By end-user, hospitals commanded 62.34% share of the kidney stone retrieval devices market size in 2024; ambulatory surgical centers are advancing at a 6.34% CAGR through 2030.
  • By geography, North America held 42.56% of the kidney stone retrieval devices market share in 2024, whereas Asia-Pacific is projected to grow the fastest at 7.12% CAGR to 2030.

Global Kidney Stone Retrieval Devices Market Trends and Insights

Driver Impact Analysi

Driver(~) % Impact on CAGR ForecastGeographic RelevanceImpact Timeline
Shift toward single-use flexible ureteroscopes+1.2%North America and Europe, expanding globallyMedium term (2-4 years)
Growing prevalence of urolithiasis in ageing populations+0.9%Especially Asia-PacificLong term (≥ 4 years)
Wider reimbursement for minimally-invasive procedures+0.8%North America and EU core; widening in APACMedium term (2-4 years)
Rapid adoption of thulium-fiber and burst-wave lithotripsy+0.7%Developed markets firstShort term (≤ 2 years)
AI-assisted endoscopic navigation reducing OR time+0.5%Early pilots in North America and EuropeMedium term (2-4 years)
ESG pressure favoring low-water, low-radiation techniques+0.3%Initially EU; gradually worldwideLong term (≥ 4 years)
Source:

Shift toward single-use flexible ureteroscopes

Clinical evidence shows that single-use scopes remove reprocessing costs, cut cross-contamination risk, and deliver comparable stone-free outcomes to reusable equivalents. Per-case expenditure ranges from USD 1,300–3,180, making them economical for facilities handling fewer than 50 cases annually. Boston Scientific’s LithoVue platform spearheads adoption, while Olympus will introduce its first single-use ureteroscope in Europe in H2 FY2025. CMS transitional pass-through payments under code C1747 bolster the kidney stone retrieval devices market by improving outpatient economics.

Wider reimbursement for minimally-invasive procedures

Medicare recognizes ureteroscopic lithotripsy as reasonable and necessary, and CMS recently assigned Category I CPT codes to Olympus’s iTind system, signaling willingness to remunerate validated innovation[1]Source: Centers for Medicare & Medicaid Services, “National Coverage Determination for Kidney Stone Treatment,” cms.gov. Field reimbursement managers and ROI calculators from Boston Scientific help providers navigate billing, smoothing adoption paths in the kidney stone retrieval devices market .

Rapid adoption of thulium-fiber and burst-wave lithotripsy

Thulium-fiber lasers shorten operative time by 20% and save USD 69 per case versus holmium:YAG systems. Japanese case series recorded basketing times of 7 minutes compared with 21 minutes for legacy lasers while maintaining equal stone-free rates. Compact consoles needing only standard outlets suit smaller clinics and expand the kidney stone retrieval devices market.

AI-assisted endoscopic navigation reducing OR time

More than 69 studies highlight AI benefits in stone recognition and outcome prediction. Early robotic flexible ureteroscopy platforms achieved 93.48% stone-free rates for stones <4 mm in initial clinical use. AI-ready optics increase differentiation inside the kidney stone retrieval devices market, yet regional data-governance gaps and uneven digital literacy slow mainstreaming[2]Source: APACMed, “Realizing the Value of AI in MedTech within Asia Pacific,” apacmed.org.

Restraint Impact Analysis

Restraint(~) % Impact on CAGR ForecastGeographic RelevanceImpact Timeline
High capital cost of digital ureteroscopes-0.8%Global; steeper in emerging marketsMedium term (2-4 years)
Device-related infection and encrustation risk-0.6%Global with variable oversightShort term (≤ 2 years)
Shortage of endourology specialists-0.5%Low- to middle-income nations, rural zonesLong term (≥ 4 years)
Supply-chain dependence on nitinol-0.4%Concentrated supplier base worldwideMedium term (2-4 years)
Source:

High capital cost of digital ureteroscopes

Reusable flexible scopes cost USD 50,000–150,000 and require supporting lasers and imaging stacks exceeding USD 200,000, delaying ROI for resource-constrained sites. Single-use scopes shift cost to operating budgets but can top USD 3,000 per case at low volume, complicating procurement decisions in the kidney stone retrieval devices market.

Device-related infection and encrustation risk

Stent encrustation risk rises after prolonged dwell times, sometimes demanding secondary surgeries. The FDA issued a class I recall on a renal-aspiration system in 2025, underscoring regulatory vigilance in the kidney stone retrieval devices market.

Segment Analysis

By Device Type: Ureteroscopes Extend Their Lead

The ureteroscope segment accounted for 34.45% of the kidney stone retrieval devices market share in 2024, which translated to roughly USD 1.06 billion of the 2025 kidney stone retrieval devices market size. Dominance stems from the instrument’s essential role in visualising and accessing calculi throughout the urinary tract, while recent upgrades in digital imaging and smaller outer diameters improve manoeuvrability and patient safety. Single-use digital ureteroscopes accelerate volume growth because hospitals can eliminate repair downtime, reprocessing expense and cross-contamination risk. Reusable fleets remain relevant in high-volume academic centres that can amortise reprocessing infrastructure and secure multiyear service contracts. Retrieval baskets and guidewires move in parallel since every ureteroscopic case requires at least one ancillary tool for fragment extraction or device placement.

Lithotripters represent the fastest-growing device class with a projected 5.34% CAGR to 2030, led by thulium-fibre laser consoles that deliver faster fragmentation with lower retropulsion than holmium:YAG systems medical.olympusamerica.com. Compact footprint, standard-outlet power requirements and embedded safety controls allow smaller ambulatory sites to adopt high-energy lasers that once belonged only in tertiary theatres. Access sheaths with suction ports shorten operative time by lowering intrarenal pressure and clearing debris in real time, a benefit that dovetails with advanced laser performance. Manufacturers are layering artificial-intelligence algorithms on top of digital video streams to automate stone detection and propose optimal laser settings, adding another point of differentiation in the kidney stone retrieval devices market. Environmental sustainability also shapes buying criteria; vendors now highlight recyclable packaging and lower water consumption during scope cleaning to align with hospital ESG goals.

By End-User: Hospitals Anchor Demand while Ambulatory Centres Accelerate

Hospitals generated 62.34% of the kidney stone retrieval devices market size in 2025, or around USD 1.91 billion, thanks to 24/7 capability, multidisciplinary backup and access to capital for premium optics. Emergency departments funnel acute renal-colic cases directly into surgical suites, underpinning steady baseline volumes. Academic centres also serve as early adopters of AI-ready scopes and simulation tools, influencing regional referral patterns. Budget committees increasingly scrutinise total cost of ownership, leading many systems to deploy mixed fleets: reusable scopes for predictable high-volume lists and single-use models for infectious or anatomically complex cases. Vendor service bundles that combine training, predictive maintenance and data dashboards help hospitals optimise asset utilisation and justify capital expense.

Ambulatory surgical centres (ASCs) are the fastest-growing channel with a 6.34% CAGR to 2030, propelled by CMS transitional pass-through payments that offset disposable scope costs and align reimbursement with outpatient economics. Same-day discharge, flexible scheduling and lower facility fees appeal to payers and patients alike, shifting straightforward sub-2 cm stones away from inpatient settings. ASCs favour single-use scopes because the devices remove the need for costly reprocessing rooms and biofilm-monitoring protocols. Specialty urology clinics move in a similar direction, often leveraging group-purchasing contracts or mobile laser-rental services to control overhead. The migration of routine procedures to outpatient venues broadens geographic access, fosters price competition and cements the kidney stone retrieval devices market as an integral component of value-based care pathways.

Geography Analysis

North America controlled 42.56 % of the kidney stone retrieval devices market in 2024, buoyed by comprehensive payer coverage and high surgeon density. Medicare reimbursement for transurethral lithotripsy and CMS pass-through payments for single-use scopes solidify procedural economics. Boston Scientific reported 23.5 % Urology segment growth in Q1 2025 as hospitals and ASCs upgraded to digital single-use platforms. Canada mirrors this trend under provincial funding, although capital constraints lengthen purchasing cycles for AI-ready consoles.

Asia-Pacific represents the fastest-growing region, expanding at a 7.12 % CAGR through 2030. Rising prevalence, urbanisation and improving insurance penetration fuel procedure volumes. China’s national data show a decisive tilt toward ureteroscopic treatment; Japan leads in thulium-fiber laser utilisation, and India’s private-insurance growth unlocks demand for cost-effective single-use scopes. Governments pursue Access-Capability-Trust frameworks to harmonise device approvals, upskill surgeons and build digital infrastructure—steps vital for sustained expansion of the kidney stone retrieval devices market.

Europe exhibits steady growth, supported by Medical Device Regulation compliance and ESG-weighted procurement criteria. Olympus is set to launch its first single-use ureteroscope in H2 FY2025, catering to hospitals aiming to reduce cross-infection and water consumption. Training deficits loom as the Simulator Availability Index for ureteroscopy trainers declined in recent surveys, hinting at potential workforce bottlenecks doi.org. South America and the Middle East participate through technology-transfer partnerships, whereas Africa faces financing hurdles and remains an untapped frontier of the kidney stone retrieval devices market.

Competitive Landscape

The kidney stone retrieval devices market is moderately consolidated. Boston Scientific commands leadership with its LithoVue single-use digital ureteroscope, reinforced by robust reimbursement support and data-monitoring tools. Olympus follows with its SOLTIVE SuperPulsed Laser and forthcoming single-use scope. Cook Medical, KARL STORZ and Dornier MedTech complete the leading cohort, each supplying complementary products—access sheaths, imaging towers, or shock-wave systems.

Strategic deals illustrate dynamic competition. Teleflex’s €760 million acquisition of BIOTRONIK’s vascular-intervention assets widens its catheter-based therapeutic arsenal . KARL STORZ’s proposal to purchase robotic-surgery firm Asensus underscores growing interest in flexible robotics and AI integration. Emerging players such as Calyxo and EndoTheia pursue niche differentiation—continuous-aspiration evacuation and steerable stone baskets respectively—offering hospitals new avenues to boost stone-free results

Beyond hardware, vendors vie in sustainability credentials, training ecosystems and digital-analytics services. Initiatives range from carbon-neutral manufacturing roadmaps to cloud dashboards that benchmark scope utilisation—features increasingly decisive in tender evaluations inside the kidney stone retrieval devices market.

Recent Industry Developments

  • February 2025: Teleflex agreed to acquire BIOTRONIK’s Vascular Intervention business for approximately €760 million, expanding its interventional portfolio
  • December 2024: Calyxo’s ASPIRE trial showed 97 % stone clearance with the CVAC System versus 93 % for standard ureteroscopy
  • November 2024: EndoTheia completed FlexStone trials, enlarging options for difficult stone retrieval
点赞 0
举报
收藏 0
评论 0
分享 0